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PImaging of Coronary Calcium
Coronary Risk Stratification, Discrimination,
and Reclassification Improvement Based on
Quantification of Subclinical Coronary Atherosclerosis
The Heinz Nixdorf Recall Study
Raimund Erbel, MD,* Stefan Möhlenkamp, MD,* Susanne Moebus, PHD,† Axel Schmermund, MD,‡
Nils Lehmann, PHD,† Andreas Stang, MD,§ Nico Dragano, PHD, Dietrich Grönemeyer, MD,¶
Rainer Seibel, MD,# Hagen Kälsch, MD,* Martina Bröcker-Preuss, PHD,** Klaus Mann, MD,**
Johannes Siegrist, MD, Karl-Heinz Jöckel, PHD,† for the Heinz Nixdorf Recall Study Investigative Group
Essen, Frankfurt am Main, Halle, Düsseldorf, Witten, and Mülheim, Germany
Objectives The purpose of this study was to determine net reclassification improvement (NRI) and improved risk prediction
based on coronary artery calcification (CAC) scoring in comparison with traditional risk factors.
Background CAC as a sign of subclinical coronary atherosclerosis can noninvasively be detected by CT and has been sug-
gested to predict coronary events.
Methods In 4,129 subjects from the HNR (Heinz Nixdorf Recall) study (age 45 to 75 years, 53% female) without overt coronary artery
disease at baseline, traditional risk factors and CAC scores were measured. Their risk was categorized into low, intermedi-
ate, and high according to the Framingham Risk Score (FRS) and National Cholesterol Education Panel Adult Treatment
Panel (ATP) III guidelines, and the reclassification rate based on CAC results was calculated.
Results After 5 years of follow-up, 93 coronary deaths and nonfatal myocardial infarctions occurred (cumulative risk
2.3%; 95% confidence interval: 1.8% to 2.8%). Reclassifying intermediate (defined as 10% to 20% and 6% to
20%) risk subjects with CAC 100 to the low-risk category and with CAC 400 to the high-risk category yielded
an NRI of 21.7% (p  0.0002) and 30.6% (p  0.0001) for the FRS, respectively. Integrated discrimination im-
provement using FRS variables and CAC was 1.52% (p  0.0001). Adding CAC scores to the FRS and National
Cholesterol Education Panel ATP III categories improved the area under the curve from 0.681 to 0.749 (p 
0.003) and from 0.653 to 0.755 (p  0.0001), respectively.
Conclusions CAC scoring results in a high reclassification rate in the intermediate-risk cohort, demonstrating the benefit of
imaging of subclinical coronary atherosclerosis. Our study supports its application, especially in carefully
selected individuals with intermediate risk. (J Am Coll Cardiol 2010;56:1397–406) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.030c
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Reclassification Based on Coronary Calcium Testing October 19, 2010:1397–406factors is well established. How-
ever, their prognostic effects de-
pend on the duration of exposure
and on the magnitude of the
deviation of the risk factors from
normal, which may vary over
time (3).
Atherosclerotic plaque forma-
tion can be regarded as the inter-
mediate between risk factor ex-
posure and clinical events and
can be imaged at a pre-clinical
stage. The quantity of coronary
artery calcification (CAC), a spe-
cific marker of coronary athero-
sclerosis, is correlated with coro-
nary atherosclerotic plaque
burden and seems to reflect the
cumulative effects of risk factors
and vascular aging (4). Clinical
studies have demonstrated its
ability to predict cardiovascular
risk (5), but methodological
shortcomings include selective
ecruitment, lack of sex-specific analysis, use of soft end
oints (i.e., revascularization or angina), and nonblinded
ssessment of results and outcome (6). In order to overcome
hese shortcomings, the HNR (Heinz Nixdorf Recall) study
as initiated (7). Meanwhile, the MESA (Multi-Ethnic Study
f Atherosclerosis) could demonstrate an incremental prognos-
ic value of CAC over traditional risk factors in a representative
.S.-American population (8,9). Similarly, biomarkers and
ther parameters are used for improvements in risk prediction.
he clinical value is expressed as their ability to reclassify
ndividual risk (10,11). We hypothesized that CAC testing can
e used for reclassification and improved risk prediction of
ard events (i.e., nonfatal myocardial infarction and coronary
eath) beyond traditional risk factors.
ethods
tudy design and population. The Heinz Nixdorf Recall
tudy is a population-based cohort study with subjects ran-
omly selected from mandatory lists of residence. Study meth-
ds have been described in detail (7,12,13). Briefly, 4,814
articipants 45 to 75 years of age were enrolled between 2000
nd 2003 in the metropolitan Ruhr area in Germany. Of these,
27 (6.8%) reported a history of CAD at baseline and were
xcluded from this analysis (Fig. 1). The CAC scores were not
eported to participants. All participants gave their written
nformed consent, and the study was approved by the institu-
ional local ethical committees.
ardiovascular risk factors. The risk factor assessment has
reviously been described (Online Appendix) (13).
isk stratification algorithms. We assessed 2 different al-
orithms for coronary risk stratification: 1) the Framingham
Abbreviations
and Acronyms
ATP  Adult Treatment
Panel
AUC  area under the
curve
CAC  coronary artery
calcification
CAD  coronary artery
disease
FRS  Framingham Risk
Score
HDL  high-density
lipoprotein
IDI  integrated
discrimination improvement
LDL  low-density
lipoprotein
NRI  net reclassification
improvement
ROC  receiver-operator
characteristic
RR  relative riskisk Score (FRS) was defined as published using LDLholesterol charts (1); and 2) in order to estimate the effect of
he high-risk variables symptomatic carotid stenosis, stroke,
eripheral artery disease, or diabetes, we allocated these sub-
ects to the high-risk category following the National Choles-
erol Education Program Adult Treatment Panel (ATP) III
lgorithm (14).
In both algorithms, participants were categorized into
ow (10% or 6% in 10 years), intermediate (10% to 20%
r 6% to 20%) and high (20%) risk categories (9–11,15).
lectron-beam computed tomography. Nonenhanced
lectron-beam computed tomography scans were performed
ith a C-100 or C-150 scanner (GE Imatron, San Fran-
isco, California) in 2 radiology institutions (D.G. and
.S.), as outlined in the Online Appendix.
ollow-up. Annual postal questionnaires and a second med-
cal examination assessed the morbidity status during follow-up
i.e., hospital admissions, outpatient diagnoses of cardiovascu-
ar disease). Participants were followed for a median of 5 years
mean 5.1  0.3 years). Exclusion of subjects is shown in
igure 1, leaving 4,129 participants (53% women) for the
resent analysis.
tudy end points and verification of study end points.
rimary end points for this study were based on unequiv-
cally documented incident coronary events that met pre-
efined study criteria (7). We considered a myocardial
nfarction event based on symptoms, signs of electrocardi-
graphy, and enzymes (levels of creatine kinase), as well as
roponin T or I, and necropsy as nonfatal acute myocardial
nfarction and coronary death (16).
For all primary study end points, hospital and nursing
ome records, including electrocardiograms, laboratory
Figure 1 Flow Chart of the HNR Study Cohort
Study cohort includes 4,487 participants 45 to 75 years of age without coronary
artery disease (CAD). MI  myocardial infarction.
B(
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October 19, 2010:1397–406 Reclassification Based on Coronary Calcium Testingaseline Characteristics of the HNR Study Population With and Without Hard EventsNonfatal Myocardial Infarction and Coronary Deaths) During 5-Year Follow-UpTable 1 B seline Ch act ristics f the HNR Study Population With and Without Hard Events(Nonfatal Myocardial Infarction and Coronary Deaths) During 5-Year Follow-Up
With Events
(n  93)
Without Events
(n  4,036) p Value
Age, yrs 62.9 8.1 59.3 7.7 0.0001
Male sex 65 (70) 1,887 (47) 0.0001
BMI, kg/m2 28.2 4.4 27.8 4.5 0.42
Overweight (BMI 25.0–29.9 kg/m2) 43 (47) 1,851 (46) 0.10
Obese (BMI 30.0 kg/m2) 30 (33) 1,071 (27)
Waist circumference, cm 98 13 94 13 0.003
Lipids
Total cholesterol, mg/dl 238 38 231 39 0.08
LDL cholesterol, mg/dl 155 35 147 36 0.02
HDL cholesterol, mg/dl 54 17 59 17 0.004
Triglycerides, mg/dl 175 112 147 99 0.004
Total cholesterol 240 mg/dl 45 (48) 1,572 (39) 0.07
Intake of lipid-lowering drugs 10 (11) 364 (9) 0.56
Total cholesterol 240 mg/dl or lipid-lowering drugs 52 (56) 1,832 (45) 0.04
Blood pressure
Systolic blood pressure, mm Hg 142 24 133 21 0.0001
Diastolic blood pressure, mm Hg 83 13 82 11 0.18
Prevalence of hypertension
JNC 7 stage 1 25 (27) 1,078 (27) 0.0004
JNC 7 stage 2 20 (22) 456 (11)
Prevalence of antihypertensive drugs 43 (46) 1,284 (32) 0.003
JNC 7 stage 1 antihypertensive drugs 61 (66) 2,198 (55) 0.03
Smoking status
Never smoked 35 (38) 1,780 (44)
Former smoker 33 (35) 1,341 (33) 0.20
Current smoker 25 (27) 915 (23)
Diabetes mellitus 16 (17) 289 (7) 0.0003
Glucose, mg/dl 121 41 110 27 0.0003
History of stroke 3 (3) 89 (2) 0.51
History of peripheral artery disease 6 (7) 48 (1) 0.001
Median serum C-reactive protein, mg/dl 0.21 (0.10/0.50) 0.14 (0.07/0.31) 0.003
Serum creatinine, mg/dl 1.02 0.55 0.92 0.21 0.0001
Risk score algorithms
Framingham risk score, % 17.5 11.4 11.3 8.3
Median, % 14 (9/22) 9 (6/14) 0.0001
Low risk, 10% 26 (28) 2,204 (54)
Low risk, 6% 7 (8) 933 (23)
Intermediate risk, 10%–20% 38 (41) 1,324 (33) 0.0001
Intermediate risk, 6%–20% 57 (61) 2,595 (64)
High risk, 20% 29 (31) 508 (13)
ATP III score
Low risk, 10% 22 (23) 2,106 (52)
Low risk, 6% 5 (5) 903 (22)
Intermediate risk, 10%–20% 33 (36) 1,157 (29) 0.0001
Intermediate risk, 6%–20% 50 (54) 2,360 (59)
High risk, 20% 38 (41) 773 (19)
CAC score 746 1,200 155 437
Median 183 (33/1,005) 11 (0/108) 0.0001
CAC score categories
0 11 (12) 1,311 (32)
1–99 24 (26) 1,666 (41) 0.0001
100–399 23 (25) 671 (17)
400 35 (37) 388 (10)
ata are expressed as n (%), mean  SD, or median (1st/3rd quartile).
ATP III  National Cholesterol Education Program Adult Treatment Panel III; BMI  body mass index; CAC  coronary artery calcification; HDL  high-density lipoprotein; JNC 7  Seventh Report of the
oint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; LDL  low-density lipoprotein.
v
c
i
w
w
e
s
c
S
p
p
(
c
m
t
d
o
b
o
w
e
s
1
m
f
d
a
w
a
1
u
t
m
S
t
i
m
d
t
H
C
r
w
F
d
b
c
s
a
s
u
3
c
O
w
v
g
e
c
w
l
m
l
(
c
9
r
c
9
e
r
S
R
B
c
a
s
NAHI6
D
1400 Erbel et al. JACC Vol. 56, No. 17, 2010
Reclassification Based on Coronary Calcium Testing October 19, 2010:1397–406alues, and pathology reports, were collected. For de-
eased subjects, death certificates were collected and
nterviews with general practitioners, relatives, and eye-
itnesses were undertaken if possible. Medical records
ere obtained in 100% of all reported end points. An
xternal end point committee blinded for risk factor
tatus and CAC scores reviewed all documents and
lassified the end points.
tatistical analysis. Based on previous studies, we hy-
othesized a relative risk (RR) 3.0 of primary end
oints in the highest versus lowest CAC score quartile
7). However, for sample size calculation, we used a more
onservative estimate of a 2.5-fold increase in the RR of
yocardial infarction or coronary death associated with
he 4th quartile compared with the 1st quartile of CAC
istribution. In order to detect an RR 2.5, a sample size
f 4,200 eligible subjects at study entry was considered to
e necessary for the primary end point analysis at a power
f 90% after 5 years. Here, we assumed 12% of subjects
ith overt coronary heart disease at baseline (to be
xcluded) and a 5-year drop-out rate of 15%. The
ignificance level (alpha error) was set at 5% for the
-sided test (7).
Demographic data and risk factors are expressed as
ean (SD) or median (25th to 75th percentile), and
requencies are given as counts (%). Quartiles of CAC
istribution were calculated by computing the common
nd the sex-specific 25th and 75th CAC percentiles
ithin the present cohort of 4,129 participants. In
ddition, pre-defined CAC score categories 0, 1 to 99,
00 to 399, and 400 were used (13).
Differences in proportions were statistically evaluated
sing chi-square or Fisher exact test and trends in propor-
ions using the Cochran-Armitage trend test; location
easures of continuous quantities were compared using
tudent t test or Mann-Whitney U test. Net reclassifica-
ion improvement (NRI) and integrated discrimination
mprovement (IDI) were derived from logistic regression
odels (17) based on Framingham risk factors (age, sex,
iabetes, systolic blood pressure, LDL and HDL choles-
erol, present smoking status) with and without CAC.
ere, we utilized the logarithmic transformation of the
AC score, log(CAC  1). For calculating the NRI,
escaled individual predicted risks from models with and
ithout log(CAC  1) were compared with established
ramingham risk thresholds. The rescaling factor was
erived by dividing the average 10-year Framingham risk
y the observed 5-year event rate. To evaluate model
alibration, we calculated the Hosmer-Lemeshow chi-
quare, which is a measure of deviation between observed
nd predicted outcomes in deciles of predicted risk.
We also give the reclassification accounting for CAC,
tarting from FRS or ATP III categories, when performed
sing pre-defined Agatston score categories (0 to 99, 100 to
99, 400) (13), with CAC 100 leading to down-
lassification and CAC 400 leading to up-classification. rriginal risk categories and the resulting new classification
ere compared by computing the NRI (17).
To assess further the ability of risk categories (or FRS
alues), log(CAC  1), and both combined to distin-
uish individuals who will develop an event, we also
stimated the receiver-operator characteristic (ROC)
urves and areas under ROC curves (AUC or c-statistic
ith 95% confidence interval [CI]) in corresponding
ogistic models (18). This was also carried out for the
odel with Framingham risk factors, with and without
og(CAC  1). C-statistics from time-to-event analyses
Harrell c), calculated as sensitivity analysis, were numeri-
ally almost identical to c-statistics from logistic regression.
Observed 5-year cumulative risks are given with their
5% CIs. We used univariate and multivariate relative risk
egression (Poisson regression with a log link) (19) to
alculate unadjusted and adjusted RRs and corresponding
5% CIs for the occurrence of primary end points. RR
stimates for CAC scores were adjusted for conventional
isk categories.
All calculations were performed with SAS (version 9.2,
AS Institute, Cary, North Carolina).
esults
aseline characteristics. Table 1 shows the distribution of
ardiovascular risk factors at baseline for participants with
nd without events. The distribution for men and women is
hown in Online Table 1.
umber of Coronary Hard Events in the 3 FRS andTP III Risk Categories and Relative Risks in theNR Study Duri g 5 Years of Follow-Up:ntermed ate R sk Thr sholds 10% to 20% a d% to 20%
Table 2
Number of Coronary Hard Events in the 3 FRS and
ATP III Risk Categories and Relative Risks in the
HNR Study During 5 Years of Follow-Up:
Intermediate Risk Thresholds 10% to 20% and
6% to 20%
Risk Category
10-Year Event Rate
No. With
Events
No. in
Group RR 95% CI
FRS
10%–20%
Low risk (10%) 26 2,230 1.00 Reference
Intermediate risk (10%–20%) 38 1,362 2.39 1.46–3.92
High risk (20%) 29 537 4.63 2.75–7.80
6%–20%
Low risk (6%) 7 940 1.00 Reference
Intermediate risk (6%–20%) 57 2,652 2.89 1.32–6.31
High risk (20%) 29 537 7.25 3.20–16.44
ATP III risk score
10%–20%
Low risk (10%) 22 2,128 1.00 Reference
Intermediate risk (10%–20%) 33 1,190 2.68 1.57–4.58
High risk (20%) 38 811 4.53 2.70–7.61
6%–20%
Low risk (6%) 5 908 1.00 Reference
Intermediate risk (6%–20%) 50 2,410 3.77 1.51–9.42
High risk (20%) 38 811 8.51 3.37–21.51
ata are expressed as n in each group and category, as well as RR with 95% CIs.
ATP  Adult Treatment Panel; CI  confidence interval; FRS  Framingham Risk Score; RR 
elative risk.
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October 19, 2010:1397–406 Reclassification Based on Coronary Calcium Testingumulative events. During 5-year follow-up, 93 (2.25%)
rimary end points occurred among 4,129 participants, including
9 coronary deaths (31%) and 64 nonfatal myocardial infarctions
69%) (Fig. 1). The number of coronary events and the relative
isks in each Framingham risk category for the total cohort are
isted in Table 2 (distribution for men and women is shown in
nline Table 2).
eclassification of risk for all risk categories. CAC cat-
gories were used for reclassification (Figs. 2A and 2B). For
xample, in the intermediate FRS category, subjects with low
Figure 2 Observed Cumulative Rates With 95% CIs of Hard Eve
and Coronary Deaths) in the HNR Study
Stratified by the Framingham Risk Score (FRS) in the risk categories of 10%, 10%
addition, the event rates in each category of coronary artery calcification (CAC) scoAC score had an event rate of only 1.4% (95% CI: 0.7% to
.5%), which was not significantly different from that in the
ow FRS category of 1.2% (95% CI: 0.8% to 1.7%) (p 0.58).
he intermediate group with high CAC score, however,
ad a risk of 8.7% (95% CI: 5.2% to 13.6%), which was
imilar to that of the total high-risk FRS cohort of 5.4%
95% CI: 3.7% to 7.7%) (p  0.10), with similar results
sing the 6% to 20% threshold for intermediate risk. Using
TP III instead of FRS influenced the results only slightly
Online Figs. 1A and 1B).
Nonfatal Myocardial Infarction
0%, and 20% at 10 years (A) and 6%, 6% to 20%, and 20% (B). In
thin each FRS category are given. Bars represent 95% confidence intervals (CIs).nts (
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Reclassification Based on Coronary Calcium Testing October 19, 2010:1397–406Reclassification of intermediate-risk subjects with CAC
100 to the low-risk category and with CAC 400 to the
igh-risk category (Table 3) resulted in correct up-
lassification of 17 (18%) and 18 (19%) and incorrect
own-classification of 12 (13%) and 27 (29%) of 93 subjects
ith events for the thresholds 10% to 20% and 6% to 20%,
espectively. Correct down-classification occurred in 836
21%) and 1,870 (46%) and incorrect up-classification
ccurred in 178 (4.4%) and 246 (6%) of 4,036 subjects
ithout events, which yielded an NRI of 21.7% (p 
.0002) and 30.6% (p  0.0001), respectively. The same
igh rates were also achieved using ATP III risk categories
Online Table 3), yielding an NRI of 18.8% (p  0.0007)
nd 29.0% (p  0.0001), respectively.
In the total cohort (Table 4), reclassification based on
escaled individual predicted event probabilities from logis-
ic regression models with and without log(CAC  1)
esulted in an NRI of 22.4% (p  0.0009) and 19.6% (p 
.004) using intermediate-risk thresholds of 10% to 20%
eclassification of Intermediate (Defined as0% to 20% and 6% to 20%) Risk Particip nts Withr Without H r Coronary Events uri g 5-Yearollow-Up Base on CAC Resul
Table 3
Reclassification of Intermediate (Defined as
10% to 20% and 6% to 20%) Risk Participants With
or Without Hard Coronary Events During 5-Year
Follow-Up Based on CAC Results
Classification According to the FRS
Reclassification Accounting
for CAC Scores
Low Intermediate High
Total
No.
10%–20%
Participants with events
Low, 10% in 10 yrs 26 0 0 26
Intermediate, 10%–20% in 10 yrs 12 9 17 38
High, 20% in 10 yrs 0 0 29 29
Total number with events 38 9 46 93
Participants without events
Low, 10% in 10 yrs 2,204 0 0 2,204
Intermediate, 10%–20% in 10 yrs 836 310 178 1,324
High, 20% in 10 yrs 0 0 508 508
Total number without events 3,040 310 686 4,036
Net reclassification improvement
(estimated)
21.7% (p  0.0002)
6%–20%
Participants with events
Low, 6% in 10 yrs 7 0 0 7
Intermediate, 6%–20% in 10 yrs 27 12 18 57
High, 20% in 10 yrs 0 0 29 29
Total number with events 34 12 47 93
Participants without events
Low, 6% in 10 yrs 933 0 0 933
Intermediate, 6%–20% in 10 yrs 1,870 479 246 2,595
High, 20% in 10 yrs 0 0 508 508
Total number without events 2,803 479 754 4,036
Net reclassification improvement
(estimated)
30.6% (p  0.0001)
ata are expressed in the intermediate-risk category for those with and without events, but
rouping all individuals in the low and high category together in one group for estimating net
eclassification improvement based on coronary artery calcification scores.
CAC  coronary artery calcification; FRS  Framingham Risk Score.nd 6% to 20%, respectively. The rescaling factor was 5.07, Aqualing 11.41 (average Framingham 10-year risk) divided
y 2.25 (observed 5-year event rate).
rude and adjusted cumulative risks in CAC score
ategories. The RR of coronary events (Table 5) for the
pper versus the lower CAC quartile was 6.40 (95% CI:
.37 to 12.16; p  0.0001). Crude cumulative risks among
ubjects with a CAC score of 100 to 399 and 400 were
early 5 and 10 times, respectively, the cumulative risk of
ubjects without CAC. For CAC scores 400, RR was
early identical in men and women (Online Table 4) and
emained highly significant when they were adjusted for the
TP III algorithm. This was not different when data were
djusted for FRS categories (data not shown).
-statistics, calibration, and IDI. AUCs were similar
mong FRS values (0.681) and the ATP III categories
0.653; p  0.14) (Figs. 3A and 3B). The AUC for
og(CAC  1) was 0.741. Adding log(CAC  1) to the 2
lgorithms significantly increased the AUCs to 0.749 and
.755, respectively (data for men and women are shown in
nline Table 5). The AUC derived from a risk prediction
odel based on Framingham risk variables (age, sex, dia-
eclassification for the Total Cohort Based onodels Using FRS Variables Wit or Withoutar Coron ry Events During 5-Year Follow-Upsed n CAC With D fini ion of Intermedia e Risks 10% t 20% and 6% to 20%
Table 4
Reclassification for the Total Cohort Based on
Models Using FRS Variables With or Without
Hard Coronary Events During 5-Year Follow-Up
Based on CAC With Definition of Intermediate Risk
as 10% to 20% and 6% to 20%
Classification Using a Model
Based on FRS Variables
Reclassification Using Models Based
on FRS Variables
With and Without CAC
Low Intermediate High
Total
No.
10%–20%
Participants with events
Low, 10% in 10 yrs 17 8 5 30
Intermediate, 10%–20% in 10 yrs 3 10 17 30
High, 20% in 10 yrs 1 5 27 33
Total number with events 21 23 49 93
Participants without events
Low, 10% in 10 yrs 2,037 290 59 2,386
Intermediate, 10%–20% in 10 yrs 429 384 283 1,096
High, 20% in 10 yrs 73 122 359 554
Total number without events 2,539 796 701 4,036
Net reclassification improvement
(estimated)
22.4% (p  0.0009)
6%–20%
Participants with events
Low, 6% in 10 yrs 4 2 0 6
Intermediate, 6%–20% in 10 yrs 9 23 22 54
High, 20% in 10 yrs 0 6 27 33
Total number with events 13 31 49 93
Participants without events
Low, 6% in 10 yrs 1,216 186 2 1,404
Intermediate, 6%–20% in 10 yrs 735 1,003 340 2,078
High, 20% in 10 yrs 29 166 359 554
Total number without events 1,980 1,355 701 4,036
Net reclassification improvement
(estimated)
19.6% (p  0.004)bbreviations as in Table 3.
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October 19, 2010:1397–406 Reclassification Based on Coronary Calcium Testingetes, LDL and HDL cholesterol, systolic blood pressure,
nd smoking) yielded an AUC of 0.712 (95% CI: 0.664 to
.760). Adding log(CAC  1) to this model increased the
UC to 0.763 (95% CI: 0.714 to 0.812; p  0.004). The
osmer-Lemeshow test yielded a chi-square of 15.5
p  0.05) for the model with Framingham risk factors and
ecreased to 9.1 (p  0.33) when log(CAC  1) was
ntered into the model. The IDI was estimated as 1.52%
p  0.0001) comparing the models with Framingham risk
actors with and without log(CAC  1).
iscussion
his large population-based study with nearly 5,000 partic-
pants and 5-year follow-up period demonstrates the fol-
owing: 1) CAC testing results in high net reclassification
ates of 21.7% and even 30.6% in participants at interme-
umulative and Relative Risks of Hard Events Associated With IncTable 5 Cumulative and Relative Risks of Hard Events Associa
No. With Events No. in Group
CAC score categories
0 11 1,322
1–99 24 1,690
100–399 23 694
400, 35 423
Log2(CAC  1) 93 4,129
Quartiles of CAC scores
1st (0) 11 1,322
2nd (0–12.4) 4 737
3rd (12.5–114.5) 23 1,037
4th (114.5) 55 1,033
ata are expressed as n in each group and category of CAC and quartiles, as well as crude and a
Abbreviations as in Table 2.
Figure 3 ROC Curve for the Prediction of Risk of Hard Events W
Using (A) the Framingham risk score (FRS) or (B) the National Cholesterol Educat
coronary artery calcification (CAC) score expressed as log(CAC  1) and the combiate risk defined as 10% to 20% and 6% to 20%, respec-
ively; 2) the use of the ATP III categories in comparison
ith the FRS yields similar results; 3) the adjusted RR
ncreases with the CAC scores; 4) a CAC score of 0
ndicates an excellent prognosis with an event rate of only
.16%/year; and 5) the CAC scoring shows significantly
etter results for c-statistics than traditional risk factors for
en as well as women.
Our findings compare well with those recently reported
y MESA (15). In that study, NRI was 25% (95% CI: 16%
o 34%). An additional 23% of subjects with events were
eclassified to the high-risk category, and 13% additional
ubjects without events were reclassified to the low-risk
ategory, which favorably compares with the 24% and 19%
f subjects, respectively, in our study, considering the
orresponding models based on Framingham variables and a
ng CAC Scores in the HNR Studyith Increasing CAC Scores in the HNR Study
rude RR 95% CI Adjusted RR* 95% CI
1.00 Reference 1.00 Reference
1.71 0.84–3.47 1.40 0.67–2.90
3.98 1.95–8.12 2.80 1.31–5.99
9.94 5.10–19.41 6.40 3.12–13.12
1.31 1.22–1.41 1.27 1.18–1.37
1.00 Reference 1.00 Reference
0.65 0.21–2.04 0.55 0.18–1.73
2.67 1.31–5.44 2.07 0.98–4.34
6.40 3.37–12.16 4.25 2.14–8.45
RR with the 95% CIs. *Adjusted for ATP III risk categories.
5 Years of Inclusion in the HNR Study
gram Adult Treatment Panel III (ATP III) score in comparison with the
of the CAC and FRS or ATP III. ROC  receiver-operator characteristic.reasited W
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ent observational and prospective studies have now shown
high NRI using a CAC-based approach. Using a multiple
iomarker model of troponin I, N-terminal pro–B-type
atriuretic peptide, cystatin C, and C-reactive protein, only
study could report a similar high NRI (26%), but in a
ohort of older adults with known CAD (10). But these
esults could not be confirmed using biomarkers like mid-
egional pro-adrenomedullin and N-terminal pro–B-type
atriuretic peptide for risk assessment (11). For other
ariables (Table 6) such as heart rate, C-reactive protein, or
emoglobin A1c, lower NRI values were reported (20–26).
hen intermediate risk was defined as 5% to 20%, the NRI
as 16.7% extrapolated to a 10-year ATP III risk for the
eynolds score in asymptomatic men (27).
On the one hand, despite these very promising results,
hysicians have to be aware that the proposed risk stratifi-
ation algorithms are not perfect, as events do rarely occur in
hose who are classified as low risk even when CAC scores
re low. On the other hand, differing from previous reports
28), a high CAC in low Framingham risk subjects was
ssociated with an event rate comparable to that of the
igh-risk group. This event rate in the low-risk subgroup
ould be further reduced when subjects with risk equivalents
ere recognized as being per se at high risk, demonstrated
n the ATP III analysis compared with the FRS results. The
vent rate was also smaller when the lower intermediate risk
hreshold was defined at 6% instead of 10% risk in 10 years.
he annual event rate in the remaining subjects was then
nly 0.12%. Extending CAC scoring to these low-risk
ndividuals would also mean a substantial increase in costs
nd unnecessary radiation exposure (29). This interpretation
ay change taking into account the 10-year or lifetime risk
RI Using Other Variables of Extended Risk StratificationTable 6 NRI Using Other Variables of Extended Risk Stratificat
Risk Marker/Factor N
Multiple biomarker score (troponin I, NT-proBNP, cystatin C, CRP)
Multiple biomarker score (MR-proADM, NT-proBNP)
HDL cholesterol (Framingham)
HDL cholesterol (SCORE data)
Heart rate (SCORE data)
hsCRP (women)
hsCRP (men)
hsCRP (men and women)
HbA1c (men)
HbA1c (women)
CAC (men and women, including revascularization)
CAC (model based on FRS-variables with and without CAC, all subjects)
CAC (reclassification based on the FRS only of intermediate-risk subjects)
odified from Cooney et al. (22). The different publications on net reclassification are related to b
elated to CAC.
CRP  C-reactive protein; HbA1c  hemoglobin A1c; hsCRP  high-sensitive C-reactive protein;
-terminal pro–B-type natriuretic peptide; other abbreviations as in Table 1.or coronary events (30), but based on the observed 5-year tvent rates, CAC scoring seems to not be indicated in
outine clinical practice for low-risk individuals.
In line with previous studies (31,32), subjects at high risk
ut low CAC scores appear to have a favorable prognosis,
ith an event rate within the range of the expected annual
.25% to 0.5% events estimated from the Duke treadmill
core (33). In these individuals, risk factor modification by
ifestyle changes may be an alternative first-line therapy.
owever, there is lack of confirmation from prospective risk
odification trials that this is safe (28,34). In addition, we
ound that in the high FRS and ATP III risk categories
ith low CAC levels, more subjects were already on risk
actor modifying therapy than in the low-risk group, which
ight have resulted in lower coronary event rates (data not
hown). Finally, other atherosclerotic end-organ manifesta-
ions in high-risk individuals cannot be neglected. There-
ore, despite the graded event rate in high-risk subjects
epending on coronary atherosclerosis burden, CAC scor-
ng in high-risk individuals has little effect on clinical
ecision making. In summary, our data support the highest
linical benefit in intermediate-risk subjects.
tudy limitations. The observed event rate of 2.25% extrap-
lates to 450 per 100,000/year and corresponds to the expected
vent rate of 300 to 500 per 100,000/year (7), and the RRs in
ur study correspond to the previous meta-analysis of CAC
coring (Fig. 4) (5). The cumulative risk was also in the
xpected range. However, the FRS overestimated risk more
han 2-fold in this European cohort, in line with previous
eports (35). Yet the FRS is the best validated risk stratification
lgorithm across various cohorts, and it did stratify our cohort
nto those with low, intermediate, and high cumulative risks,
ven though the expected thresholds were not reached. Fur-
)
Intermediate 10-Yr
Risk Definition (%) p Value First Author (Ref. #)
6–20 0.005 Zethelius et al. (10)
6–20 NS Melander et al. (11)
6–20 0.001 Pencina et al. (17)
2–5 and 5–10 0.006 Cooney et al. (23)
2–5 and 5–10 NS Cooney et al. (24)
5–20 0.0001 Cook et al. (25)
5–20 0.001 Wilson et al. (26)
6–20 0.009 Ridker et al. (27)
5–10 and 10–20
0.06
Simmons et al. (21)
0.27
6–20 0.001 Polonsky et al. (15)
6–20 0.004 Erbel et al. (current study)
10–20 0.0009
6–20 0.0001 Erbel et al. (current study)
10–20 0.0002
ers, HDL cholesterol, heart rate, and signs of diabetes. In addition, results of our study are listed
ADM  mid-regional pro-adrenomedullin; NRI  net reclassification improvement; NT-proBNP ion
RI (%
26.0
4.7
12.1
2.2
1.1
5.7
8.4
11.8
3.4
–2.2
25.0
19.6
22.4
30.6
21.7
iomarkhermore, the FRS (36) has been developed to identify coro-
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hich is in line with our study goals.
We cannot exclude that other more recently proposed
lgorithms (2,37,38) would have predicted events better
han the algorithms used in this analysis, given that other
lgorithms have in part used different end points or were
eveloped based on selected populations.
Finally, a cost-effectiveness analysis is warranted when eval-
ating a novel marker of cardiovascular risk (39). This requires
thorough investigation of medication prescription data,
hich is part of a separate ongoing health-economic project
nd will be the focus of a separate forthcoming report.
onclusions
AC scoring improves risk stratification, discrimination,
nd reclassification above and beyond traditional risk factor
ategories. Limiting CAC scoring to intermediate-risk sub-
ects helps to correctly identify a high proportion of indi-
iduals at highest risk and can contribute to reducing the
umber of coronary events in the general population.
owever, physicians should be aware that these algorithms
re not perfect, particularly in the low-risk category.
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